Investing.com - Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) reported second quarter EPS of $-0.64, $0.38 better than the analyst estimate of $-1.02. Revenue for the quarter came in at $49.86M versus the consensus estimate of $32.26M.
Arcturus Therapeutics Holdings Inc's stock price closed at $19.79. It is down -26.13% in the last 3 months and down -38.29% in the last 12 months.
Arcturus Therapeutics Holdings Inc saw 1 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Arcturus Therapeutics Holdings Inc's stock price’s past reactions to earnings here.
According to InvestingPro, Arcturus Therapeutics Holdings Inc's Financial Health score is "good performance".
Check out Arcturus Therapeutics Holdings Inc's recent earnings performance, and Arcturus Therapeutics Holdings Inc's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar